The Biologics Price Competition and Innovation Act turned fifteen years old in March, and the procedural ritual it created keeps […]

The pharmaceutical industry has always run on information asymmetry. The company that knows, six months before its competitors, that a

A practitioner’s guide for IP teams, generic manufacturers, and pharmaceutical investors who need to decode what a competitor’s formulation patent

There is a moment, familiar to every generic drug executive, when a promising target drug goes from ‘opportunity’ to ‘nightmare.’

The call came on a Tuesday morning. A general counsel at a mid-sized specialty pharma company had just received a

By the time a generic development team discovers that a drug’s composition-of-matter patent expires in three years, the real work

Every patent a pharmaceutical company files is a sworn, detailed confession. It tells you what the company’s chemists have been

Who this is for: Formulation scientists, regulatory affairs directors, IP counsel, and business development executives at generic and specialty pharmaceutical

Every year, somewhere between $20 billion and $80 billion in branded drug revenue falls off a cliff. Not metaphorically. Literally: